Welcome and Opening Remarks

Richard L. Schilsky, M.D., FACP, FSCT, FASCO Chairman, WIN Consortium
Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology (ASCO®), Alexandria, USA

Josep Tabernero, M.D., PhD, Vice-Chairman, WIN Consortium
Vall d’Hebron Institute of Oncology (VHIO), Spain, President European Society for Medical Oncology (ESMO), Switzerland
John Mendelsohn

31 August 1936 – 7 January 2019
“We can accomplish more together than each organization can achieve working alone”

- 20 countries over 4 continents
- 27 academic cancer centers - Access to patients from different populations
- 6 industries – Access to drugs and technologies
- 3 cancer patient organizations – The voice of the patients
MISSION

Significantly improve survival and quality of life of cancer patients across the world.

STRATEGY

- Perform proof of concept trials designed to explore novel strategies and tools aiming to:
  - Increase efficacy of Precision Oncology for advanced cancers and access to patients worldwide
  - Improve early diagnosis
- Share information about state of the art research across the world, the work of WIN members, WIN trials and more generally promoting the adoption of personalized cancer medicine globally through an annual symposium.
## WIN Consortium Members

### Academic Institutions in Americas
- The University of Texas MD Anderson Cancer Center
- UC San Diego Moores Cancer Center
- Avera Cancer Institute
- Segal Cancer Centre at the Jewish General Hospital

### Industries
- Pfizer Oncology
- Merck
- AstraZeneca
- Covance
- Illumina
- HTG Molecular

### Academic Institutions in Asia
- Finnish University of 1905
- Tata Memorial Centre
- Global Dental University
- Gachon University Gil Medical Center
- Sookmyung Women's University
- The Chaim Sheba Medical Center at Tel Hashomer - Est. 1948, The Hospital of Israel
- Ben-Gurion University of the Negev
- King Hussein Cancer Foundation

### Academic Institutions in Europe
- VHIO Vall d’Hebron Institute of Oncology
- INCLIVA VLC Biomedical Research Institute
- CHL Centre Hospitalier de Luxembourg
- Luxembourg Institute of Health
- Fondation ARC pour la Recherche sur le cancer
- European Cancer Patient Coalition
- Surviveit

### Non-Profit Organisations
- Righospitalet
- Tartu University Hospital
- UMF Université de Medicine et Pharmacie de Lüttich
- The Oncology Institute Prof. Dr. Ion Chiriță
- Groupe hospitalier Paris Saint-Joseph

### 20 countries in 4 continents

www.winconsortium.org
Our Principal Investigators

Razelle Kurzrock
Senior Deputy Center Director
Director, Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, USA

Brian Leyland-Jones
Director, The Darwin Foundation

Jean-Charles Soria
Past Head of Phase I Unit, Gustave Roussy, Villejuif, France
Senior Vice President, Head of Oncology Innovative Medicines, MedImmune, USA

Enriqueta Felip
Head of Lung Cancer Unit, Oncology Dept, Vall d’Hebron Institute of Oncology, VHIO, Spain

Jordi Rodon
Past Clinical Head & Co-Director, Vall d’Hebron Institute of Oncology, VHIO, Spain
Dept. of Investigational Cancer Therapeutics M.D. Anderson Cancer Center, University of Texas, USA

Apostolia-Maria Tsimberidou
Professor, Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, University of Texas, USA

Lyudmila Bazhenova
Prof. of Clinical Medicine, University of California San Diego Moores Cancer Center, USA

Benjamin Solomon
Assistant Professor of Medicine, Avera Cancer Institute, USA

Raanan Berger
Director, Institute of Oncology, Sheba Medical Center, Israel

Jair Bar
Head of the Thoracic Oncology, Sheba Medical Center, Israel

Wilson Miller
Professor, Division of Oncology, Segal Cancer McGill University, Canada

Guy Berchem
Medical Oncologist, Centre Hospitalier du Luxembourg

Pierre Saintigny
Department of Translational Research, Centre Léon Bérard, France

Jean-Yves Blay
Director, Centre Léon Bérard, France

Nicolas Girard
Head of Department, Medical Oncology, Institut Curie, France
Our Principal Investigators - Cont.

Eric Raymond
Groupe Hospitalier Paris St Joseph, France

Ulrik Lassen
Rigshospitalet, Denmark

Andrés Cervantes
INCLIVA, Spain

Tamar Peretz
Hadassah University, Israel

Ioana Berindean Neagoe
University of Medicine & Pharmacy, Romania

Rares Buiga
Oncology Institute Ion Chiricuta, Romania

Peeter Padrik
Tartu University Hospital, Estonia

Marina Sekacheva
Sechenov University, Russia

Amal Al Omari
King Hussein Cancer Center, Jordan

David Cantú
Instituto Nacional de Cancerología, Mexico

Luis Eduardo
Rosa Zucca
Barretos, Brazil

Masashi Kanai
Kyoto University Hospital, Japan

Sadakatsu Ikeda
Tokyo Medical and Dental University, Japan

Sung Min Ahn
Gachon University Gil Medical Center, Korea

Xi Chen
Fudan University Shanghai, China

C S Pramesh
TATA Memorial Hospital, India
Today precision oncology is based on DNA sequencing.
WIN Consortium explores beyond the tip of the iceberg towards a new integrated model for Precision Oncology

**GENOMICS**

**TRANSCRIPTOMICS**

New strategy based upon:
- Dual Tumor & Normal biopsies
- Drug knowledge database
- WINTHER* & SIMS** integrative algorithms for predicting efficacy of a plurality of drugs alone or in combinations

*Published in Nature Medicine  https://doi.org/10.1038/s41591-019-0424-4
** Trial SPRING 01 tritherapy in NSCLC in progress
WIN Consortium International PO Trials Track Record

**COMPLETED - WINther trial - NCT01856296 (*)**

First navigation trial using both genomics and transcriptomics to direct patients with advanced cancer to personalized therapies (including clinical trials).

- Use of DNA and mRNA investigations
- Use of a biopsy of both Tumor and Normal tissue (to account for variation in transcription levels)
- Use of the WINther algorithm
- 5 countries (France, Spain, Israel, Canada, USA)
- 8 academic and 3 industry members of WIN participated
- Principally funded by European (EU FP7) grant, Foundation ARC and Pfizer

https://doi.org/10.1038/s41591-019-0424-4

---

Genomic and transcriptomic profiling expands precision cancer medicine: the WINther trial

After WINTHER comes ....

**SPRING**

Family of Tri-therapy combinations of existing targeted drugs in Stage IV NSCLC following the successful strategy in the treatment of AIDS.

Hypothesis: Different modes of action will be able to achieve what targeted single agents have failed to do so far in precision oncology, especially in lung cancer — stave off cancer resistance and prolong longterm survival.
ONGOING Phase I – SPRING 01 IND clinical trial Phase I/II - NCT03386929 - IND 131601

First trial investigating a triple therapy combination (avelumab, palbociclib, and axitinib – Pfizer and Merck KGaA) for metastatic/advanced NSCLC in first line of treatment.

- Use of DNA, mRNA and MIR investigations
- Use of a biopsy of both Tumor and Normal tissue (to account for variation in transcription levels)
- Use of the integrative SIMS(*) algorithm
- 5 countries (USA, Spain, Israel, France, Luxembourg)
- 9 academic and 3 industry members of WIN participating
- Supported by WIN members, funded by Foundation ARC, drugs provided by Pfizer/Merck KGaA

The journey continues

- Developing a global translational research network is hard
- Requires vision, passion, energy, commitment, leadership, willingness to take risks
- The vision of WIN’s leaders is now reality
- WIN is a legally constituted, global research network
- WIN has completed a proof of concept, highly innovative clinical trial
- WIN will change the lives of cancer patients and the direction of cancer research
- But only with the continuing support of everyone here today